他描述了他在人类胚胎中使用CRISPR-Cas9来抑制CCR5基因的工作。他声称这两个基因编辑过的胚胎随后被植入母体，双胞胎婴儿已经出生。
贺博士及其团队的这项工作，非常令人不安地冲击了国际道德规范。
该项目是秘密进行的，灭活这两个婴儿的CCR5基因的理由，从医学上不能令人信服。
公布的操作过程，非常值得怀疑。并且，贺博士对排除“脱靶效应”可能性方面的解释，非常让人不满意。
很不幸的是，基因剪辑这种强有力的技术，已经如此不负责任地首次在人类身上进行开了。
现在科学界正在香港进行辩论，是否需要就此类研究制定具有约束力的国际共识，这一点从未如此急迫。
如果没有这种限制，世界将面临大量同样的不道德的项目泛滥的风险。
如果这种惊人的、不幸的科学事件继续发生，那么此类技术对于预防和治疗疾病方面原本具有的巨大的潜力，将被公众的愤怒、恐惧和厌恶所淹没。
为了避免出现任何疑问，正如我们之前所说，NIH不支持在人类胚胎中使用基因编辑技术。
Francis S. Collins，M.D.，Ph.D,
弗朗西斯·柯林斯，医学、化学双博士
国立卫生研究院院长
链接：
https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-claim-first-gene-edited-babies-chinese-researcher
英文原文：
NIH is deeply concerned about the work just presented at the Second International Summit on Human Genome Editing in Hong Kong by Dr. He Jiankui, who described his effort using CRISPR-Cas9 on human embryos to disable the CCR5 gene.
He claims that the two embryos were subsequently implanted, and infant twins have been born.
This work represents a deeply disturbing willingness by Dr. He and his team to flaunt international ethical norms.
The project was largely carried out in secret, the medical necessity for inactivation of CCR5 in these infants is utterly unconvincing, the informed consent process appears highly questionable, and the possibility of damaging off-target effects has not been satisfactorily explored.
It is profoundly unfortunate that the first apparent application of this powerful technique to the human germline has been carried out so irresponsibly.
The need for development of binding international consensus on setting limits for this kind of research, now being debated in Hong Kong, has never been more apparent.
Without such limits, the world will face the serious risk of a deluge of similarly ill-considered and unethical projects.
Should such epic scientific misadventures proceed, a technology with enormous promise for prevention and treatment of disease will be overshadowed by justifiable public outrage, fear, and disgust.
Lest there be any doubt, and as we have stated previously, NIH does not support the use of gene-editing technologies in human embryos.
Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health
